Abiopharma

🔍 WEINSTOCK DAVID B (Executive)

Company: Essent Group Ltd. (ESNT)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Acquired 8,333 shares of Common shares, par value $0.015 (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 44,232.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 527 shares of Common shares, par value $0.015 (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 44,759.00 | transaction_form_type: 4 | Footnotes: F2, F2
• Sold 3,765 shares of Common shares, par value $0.015 at $58.25 per share (Direct)
  Date: 2026-04-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 40,994.00 | transaction_form_type: 4
• Sold 8,333 shares of Restricted share units (Derivative)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 67,573.00 | transaction_form_type: 4 | Footnotes: F1, F3, F1, F1
• Sold 527 shares of Dividend equivalent units (Derivative)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 2,180.00 | transaction_form_type: 4 | Footnotes: F2, F2, F2

Footnotes:

• F1: Restricted share units convert into common shares on a one-for-one basis.
• F2: The dividend equivalent rights accrued on unvested restricted stock award(s) and/or unvested restricted stock unit award(s) and become vested proportionately with the award(s) to which they relate. Each dividend equivalent unit is the economic equivalent of one common share of Essent Group Ltd.
• F3: On March 14, 2023, the reporting person was granted 25,000 restricted share units, vesting in equal installments on each of April 1, 2026, 2027 and 2028.